principle bile acids synthesized in the liver are cholic acid and chenodeoxycholic acid, and extensive conjugation with primarily glycine and taurine occurs within the hepatocyte. The active transport of solutes across the canalicular membrane is the rate-limiting step in bile formation [2, 5] .
When compared with the adult liver, the liver of the term infant is immature in both metabolic and excretory functions. Bile fl ow can be divided into bile acid-dependent and bile acid-independent fl ow, with the former providing the primary force of generating bile fl ow early in life. As a consequence of the immaturity of the hepatic metabolic and excretory functions, TPN induces liver changes that could be directly related to the kind of artifi cial nutrition and, in part, to the way the nutrients are administered. As described previously [3] , these changes can be divided into three types: direct, adaptive and pathologic.
Pruritus
Pruritus can be a troublesome manifestation of cholestasis. Cholestatic pruritus is uncommon in the neonatal period, with the exception of diseases including paucity of bile ducts, such as Allagile syndrome, and the progressive familial intrahepatic cholestasis syndromes. The prevalence of pruritus in liver disease is more common in older infants, children and adults. Pruritus
Cholestasis is a frequent occurrence in newborns, affecting one in every 2500 infants. Immaturity of hepatic metabolic and excretory functions contributes to decreased bile production and transport. The potential causes of neonatal cholestasis are extensive, but most cases fall into a few categories, including anatomic, metabolic and infectious. Pruritus and malabsorption are common manifestations of neonatal cholestasis, regardless of etiology. Medical management of cholestasis is largely supportive, treating the complications of cholestasis rather than the underlying mechanism. Medications for pruritus have variable effi cacy and include ursodeoxycholic acid, cholestyramine and rifampin. Fat-soluble vitamin supplementation is often required secondary to fat malabsorption. Enteral absorption of long-chain triglycerides is also decreased, necessitating formulas high in medium-chain triglycerides. Infants may require 125% of the recommended daily allowance of calories for adequate growth and supplementation with enteral feeding tubes may be required.
future science group REVIEW Best & Gourley can be persistent or inter mittent, and may be generalized or localized to specifi c areas, such as the palms and soles. Physical and psycho logical processes can exacerbate the pruritus and management is often diffi cult.
The exact cause of pruritus has yet to be determined but most researchers agree that more than one factor is involved in the pathogenesis of pruritus in cholestatic infants. Traditionally, it has been assumed that pruritus arises secondary to the accumulation of pruritogenic substances in the bile. Bile acids have been the most studied of such substances, with varied conclusions [6] [7] [8] .
Inconsistencies in the bile salt-pruritus interaction have prompted the hypothesis that bile salts may act directly on the liver, causing the release of a pruritogenic compound.
More recently, the focus has shifted to a theory implicating endogenous opioids as central mediators of pruritus, as the occurrence of pruritus with opioid mediation is well known [9] . The role of the serotonin neurotransmitter systems have also been studied regarding their potential role in causing cholestasis-induced pruritus. Serotonin has been shown to be involved with cholestasis-induced fatigue, but less is known regarding its role in cholestasis-induced p ruritus [10, 11] . One of the major complications of cholestasis is fat malabsorption. Failure to secrete bile salts secondary to cholestasis results in a defi ciency of bile salts in the intestine. Intraluminal bile acid concentration falls below the critical micellar concentration and micelles are not formed correctly, leading to malabsorption [12] .
Failure to thrive can be a signifi cant consequence of fat malabsorption and monitoring of growth parameters is essential, with nutritional supplementation when indicated. Although medium-chain triglycerides are absorbed more readily by the intestinal mucosa than LCTs, they cannot be used alone since essential fatty acid defi ciency can result. Signs of fatty acid deficiency include fl aky, dry skin, poor hair growth, thrombocytopenia and poor wound healing [2] .
The fat-soluble vitamins A, D, E and K require solubilization by bile acids into micelles in order to be absorbed across the intestine. Cholestatic infants are particularly susceptible to fat-soluble vitamin defi ciency as a consequence of malabsorption. Vitamin A defi ciency was estimated to occur in 43% of cholestatic infants in one study [13] . Xerophthalmia, or 'dry eye', is the most recognized manifestation of vitamin A defi ciency which, if left untreated, can progress to corneal ulceration. Vitamin D defi ciency in cholestatic infants predisposes them to metabolic bone disease. Of note, some patients may have bone disease that persists despite normal levels of serum 25-hydroxyvitamin D, suggesting that other hormonal or nutritional parameters may be important in the development of bone disease in infants with cholestasis [14] . Addressing chronic vitamin E defi ciency is of particular importance as it can lead to a progressive neuro muscular syndrome characterized by arefl exia, peripheral neuropathy and posterior column dysfunction. Anemia can also be a manifestation of vitamin E defi ciency. Vitamin K defi ciency may be a presentation of cholestasis and intracranial hemorrhage secondary to vitamin K defi ciency, and continues to be a frequent cause of death in infants with cholestasis [2] . Vitamin K is required for some coagulation proteins, such as factors II and VII, with defi ciency leading to an increased propensity to bleeding [15] .
Intestinal absorption of calcium and phosphorus is decreased in malabsorption secondary to cholestasis due to the formation of insoluble soaps. Such defi ciency can contribute to bone disease that is unresponsive to vitamin D supplementation, and enteral supplements may be required to reverse bone disease.
Micronutrients can also be affected by cholestasis. Zinc is an essential trace element, present in over 100 metalloenzymes, and low plasma zinc is common in cholestasis. Plasma zinc concentrations do not correlate well with total body zinc status, making diagnosis of zinc deficiency difficult [16] . Selenium functions as an antioxidant, catalyzing the reduction of hydrogen peroxide and lipid hydroperoxidases. Selenium defi ciency has been reported in 13-33% of children with cholestasis [17] . Mild defi ciency is defi ned as a plasma selenium level less than 40 µg/l and severe defi ciency as a level less than 10 µg/l.
Management of cholestasis
The medical management of cholestasis is largely supportive. Management is often related to the treatment of the complications of chronic cholestasis rather than the underlying mechanism. These complications include pruritus, malabsorption and nutritional defi ciencies.
Pruritus
Cholestatic pruritus is probably a result of multiple mechanisms. Utilizing combination therapy with agents with varying mechanisms of action may be benefi cial (see TABLE 1 ).
Ursodeoxycholic acid (UDCA) is a hydrophilic choleretic agent that increases bile fl ow and reduces membrane toxicity by hydrophobic bile acids [18] . Studies regarding the effi cacy of UDCA in the treatment of cholestatic disease have shown confl icting results. In a 2.5-year, open-label, crossover study to determine the effects of UDCA on the clinical symptoms and biochemical test results of 13 patients with intrahepatic cholestasis, Narkewicz et al., found that all patients with pruritus experienced symptomatic improvement with treatment as well as improvement in biochemical parameters [19] . UDCA is generally safe, although diarrhea is an uncommon side effect in the pediatric population. The dosage of UDCA is 10-30 mg/kg/day in divided doses.
Cholestyramine is a nonabsorbable, nonspecifi c anion exchange resin that binds bile acids, decreasing enterohepatic circulation by preventing their reabsorption in the terminal ileum [2] .
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There has been no randomized study to assess the effi cacy of cholestyramine but it has been shown to improve pruritus in the majority of patients within the fi rst 2 weeks of treatment, although response may be transient. Recommended dosing of cholestyramine is 240 mg/kg orally in three divided doses, with the initial dose limited to 1 g daily. Dosing can be adjusted to a recommended maximum dosage of 4 g daily in children who are 10 years of age and younger and 8 g for those older than 10 years [20] . As the greatest amount of bile acids available for binding are thought to be in the gallbladder in the morning, cholestyramine administration is recommended 30 min prior to both breakfast and lunch, as well as 30 min after lunch [21] . In addition to a diffi cult dosing regimen, cholestyramine has a poor palatability making it diffi cult to give to children. Other side effects, although mild, include constipation, abdominal discomfort, anorexia and fat malabsorption. Hypoproteinemic hemorrhage and hyperchloremic metabolic acidosis after cholestyramine have been described in case reports [22] . Cholestyramine also interferes with the absorption of several drugs, including UDCA, thyroxin and oral contraceptive pills, and it is recommended that no other medications should be taken within 4 h of cholestyramine ingestion when feasible.
Phenobarbital is a microsomal enzyme inducer that can stimulate bile acid-independent fl ow and decrease bile acid-pool size [2] . Phenobarbital is used less frequently owing to its sedating side effect. The therapeutic dose of phenobarbital is 5-10 mg/kg/day. Rifampin, another microsomal enzyme inducer, also enhances bile acid detoxifi cation, and bilirubin conjugation and excretion [23] . In a non-placebo-controlled open trial of 24 children with cholestatic pruritus, unresponsive to other treatments, Yerushalmi et al. found that rifampin dosed at 10 mg/kg/day resulted in complete or partial response in 90% of the patients [24] .
UV phototherapy is used to treat a variety of pruritic conditions. In a study of eight patients with cholestatic liver disease and pruritus, phototherapy did not result in signifi cant improvement in pruritus [25] .
If medical treatment fails and pruritus is severe, partial biliary diversion (biliary drainage through a stoma) or partial ileal bypass may be successful in relieving cholestatic pruritus [26] . By decreasing the load of bile acids to the ileum, the sole site of bile acid transport, enterohepatic circulation is lessened. Such diversion has been shown to provide relief from pruritus and, perhaps, reversal of liver disease in patients with progressive familial intrahepatic cholestasis with a low or normal γ-glutamyl transferase level [27] . In addition, biliary diversion should be considered in patients with arteriohepatic dysplasia (Allagile syndrome) who have symptoms refractory to medical therapy [28] .
Malabsorption & nutritional defi ciencies
As discussed earlier, UDCA is a choleretic agent that may decrease the degree of cholestasis in some settings. One function of UDCA is to increase the rate of transport of intracellular bile acids across the canalicular membrane [1] . Besides cholestasis-induced pruritus, UDCA is often used as fi rst-line therapy for TPN-induced cholestasis and biliary atresia.
The ratio of serum vitamin E (mg/dl) to total serum lipids (g/dl) has been described as the most reliable index of vitamin E defi ciency. This is due to the fact that cholestasis results in elevated serum lipids into which vitamin E can partition, causing an artifi cial elevation in the serum vitamin E concentration. A ratio less than 0.6 mg/g in infants and children aged less than 12 years or a ratio less than 0.8 mg/g in those older than 12 years indicates vitamin E deficiency [2] . For vitamin E defi ciency, if cholestatic infants do not correct with traditional vitamin E [29] . TPGS offers the advantage of being free from toxicity and obviating the need for intramuscular administration. TPGS can also be used as a vehicle for co-administering other fat-soluble vitamins. Supplementation with vitamin A should begin after documenting vitamin A defi ciency using either serum retinol or relative doseresponse testing. Serum retinol testing has been estimated to have a sensitivity of 90% in detecting vitamin A defi ciency and a specificity of only 78%, limiting testing for screening purposes. An additional test for vitamin A defi ciency, the relative dose response (RDR), is a functional test of vitamin A reserves and has been found to be an accurate, noninvasive test to determine actual vitamin A status in patients with chronic liver disease. Feranchak et al. developed an oral version of the typical intramuscular RDR. After a small oral dose of vitamin A (1500 IU Aquasol A combined with 25 IU/KG TPGS) is given, the plasma retinol increases markedly if hepatic vitamin A stores are low [13] . Oral vitamin A supplementation for cholestatic infants is recommended with Aquasol A and doses range between 3000 and 25,000 IU/day. Supplementation of vitamin D should begin after documenting a serum 25-hydroxyvitamin D below 15 ng/ml. As with other fat-soluble vitamin supplementation, absorption of vitamin D by the gastrointestinal tract can be enhanced by co-administration with TPGS [30] . If the vitamin D level is above 15 ng/ml, periodic 25-hydroxyvitamin D level testing is continued. Supplementation is recommended with vitamin D2 (Drisdol) at 3-10× RDA for age using at least 400 IU or 25-hydroxyvitamin D (Calderol), using a dose of 3-5 µg/kg/day [17] .
Supplementation of vitamin K should begin after documentation of defi ciency. Prolongation of the prothrombin time (PT)/International Normalized Ratio in comparison with the partial thromboplastin time suggests a vitamin K defi ciency. Response of the PT to intramuscular injection of vitamin K is the most accurate mode of assessing vitamin K defi ciency [17] . Supplementation of vitamin K is recommended with Mephyton ® , using a dosing range between 2.5 mg biweekly and 5.0 mg/day.
For water-soluble vitamin supplementation in infants with cholestasis, most believe that it is prudent to supplement with a multivitamin at one-to two-times the RDA. Defi ciencies Enteral supplementation with elemental calcium and phosphorus should commence after documentation of low serum concentration of calcium and/or phosphorus [31] . Magnesium deficiency should be documented with a low serum level and treated with magnesium oxide to minimize decreased bone mineral density secondary to cholestasis [32] . It has been recommended that in infants who are growing poorly with inadequate oral intake or low plasma zinc concentration (60 µg/dl), supplementation for 2-3 months as a therapeutic trial should be instituted [17] .
Supplementation with selenium is recommended at 1-2 µg/kg per day for defi ciency and 1 µg/kg per day for those on total TPN for maintenance. Nutrient levels should be monitored periodically during treatment. TABLE 2 provides a summary of medications used to treat nutritional defi ciencies in neonates with cholestasis.
Future perspective
Research will further increase knowledge regarding the transport of bile acids and specifi c molecular defects that lead to clinical disease. Such knowledge will allow specifi c therapies to be developed that target individual diseases, or specifi c cellular processes, leading to improved treatment efficacy. In addition, increased knowledge regarding molecular defects associated with cholestatic liver disease will allow the number of disorders classifi ed as idiopathic neonatal cholestasis to decrease as specifi c diagnoses are made. 
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Executive summary
Pathophysiology
Cholestasis is defi ned as impaired canalicular bile fl ow. Most causes can be categorized as anatomic, metabolic and infectious. Hepatic metabolic and excretory function is immature in the newborn. Active transport of solutes across the canalicular membrane is the rate-limiting step in bile formation. Bile fl ow can be divided into bile acid-dependent fl ow and bile acid-independent fl ow with the former most important early in life.
Pruritus
Pruritus is more common in intrahepatic bile duct paucity and progressive familial intrahepatic cholestasis.
Mechanisms may involve accumulation of pruritogenic substances in the bile, endogenous opioids and the serotonin neurotransmitter systems.
Malabsorption
Failure to secrete bile salts impairs absorption of fats and fat-soluble vitamins. Micelles are required for absorption fats, particularly long-chain fatty acids.
Management of pruritus
Medical management of cholestasis is largely supportive. Ursodeoxycholic acid is a choleretic agent that alters the bile acid pool and increases the rate of canalicular bile acid transport. Cholestyramine is a nonabsorbable nonspecifi c anion exchange resin that binds bile acids, decreasing enterohepatic circulation. Phenobarbital and rifampin are microsomal enzyme inducers that can stimulate bile acid-independent fl ow. Effi cacy of phototherapy for cholestatic pruritus has not been proven. Biliary diversion may be benefi cial in those with severe pruritus not controlled with medical therapy.
Management of malabsorption
Medium-chain triglycerides are absorbed more readily by the intestinal mucosa than long-chain fats. Supplementation with fat-soluble vitamins A, D, E and K is frequently needed.
Chronic vitamin E defi ciency can lead to a progressive neuromuscular syndrome. Use of oral d-α-tocopherol polyethylene glycol 1000 succinate can aid in the absorption of other fat soluble vitamins. Supplementation with a multivitamin at once or twice RDA may be prudent. Serum levels of calcium, phosphorus, magnesium, selenium, and zinc should be monitored and appropriate supplementation instituted after documenting defi ciency.
